Literature DB >> 11741169

Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors.

Daisy M Machado1, Eric L Delwart, Ricardo S Diaz, Carlos F de Oliveira, Katia Alves, Bhupat D Rawal, Marian Sullivan, Marta Gwinn, Kenneth A Clark, Michael P Busch.   

Abstract

OBJECTIVE: To corroborate the validity of the recently developed sensitive/less sensitive (S/LS) dual enzyme immunoassay (EIA) strategy for the detection of recently infected individuals and to genetically analyze recently transmitted strains of HIV-1 in a US blood donor population.
DESIGN: The S/LS EIA strategy was used to identify 33 recently infected subjects among 281 enrolled HIV-1 seropositive blood donors (from a total of 410 HIV-1 infected subjects identified from 5 230 463 blood donations screened by participating US blood centers in 1995-1996).
METHODS: We analysed three host response and viral characteristics were associated with recent HIV-1 infection: rapidly increasing EIA optical density (OD) values, genetically homogeneous env gene quasispecies, and putative non-syncytium inducing env V3 loop sequences. The drug resistance genotypes of the recently transmitted strains were determined by DNA sequencing.
RESULTS: Increasing EIA OD values, clonal HIV-1 quasispecies and V3 loop sequences with inferred NSI phenotypes were generally detected in LS EIA non-reactive samples. Thirty-two subtype B and one CRF02_AG recombinant HIV-1 were detected. Genetic evidence for drug resistance to zidovudine (K70R) and non-nucleoside analog reverse transcriptase inhibitors (V108I) was detected in one strain each, and three other strains showed the presence of accessory protease inhibitor resistance mutations.
CONCLUSIONS: Immunologic and virologic results further substantiate the validity of the S/LS EIA strategy for the detection of recent infections and illustrate its use for targeting molecular and epidemiological investigations to incident cases identified from large cross-sectional screening programs, rather than the more costly and logistically difficult longitudinal studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11741169     DOI: 10.1097/00002030-200201040-00014

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Incidence of recent human immunodeficiency virus infection at two voluntary counseling testing centers in Pernambuco, Brazil, from 2006 to 2009.

Authors:  Kledoaldo Oliveira de Lima; Daniela Medeiros Salustiano; Maria Rosângela Cunha Duarte Coêlho; Ana Maria Salustiano Cavalcanti; Ricardo Sobhie Diaz; Heloísa Ramos Lacerda
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method.

Authors:  Barbara Suligoi; Claudio Galli; Mario Massi; Fiorella Di Sora; Mauro Sciandra; Patrizio Pezzotti; Olga Recchia; Francesco Montella; Alessandro Sinicco; Giovanni Rezza
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Discrimination between recent and non-recent HIV infections using routine diagnostic serological assays.

Authors:  Jaythoon Hassan; Joanne Moran; Gary Murphy; Olivia Mason; Jeff Connell; Cillian De Gascun
Journal:  Med Microbiol Immunol       Date:  2019-03-11       Impact factor: 3.402

4.  Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections.

Authors:  Elisa Martró; Barbara Suligoi; Victoria González; Vincenzo Bossi; Anna Esteve; Joanne Mei; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors.

Authors:  Eric Delwart; Elizabeth Slikas; Susan L Stramer; Hany Kamel; Debra Kessler; David Krysztof; Leslie H Tobler; Danielle M Carrick; Whitney Steele; Deborah Todd; David J Wright; Steven H Kleinman; Michael P Busch
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

6.  Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002.

Authors:  Carmem A de Freitas Oliveira; Mirthes Ueda; Rosemeire Yamashiro; Rosângela Rodrigues; Haynes W Sheppard; Luís Fernando de Macedo Brígido
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1.

Authors:  Kimberly Ritola; Christopher D Pilcher; Susan A Fiscus; Noah G Hoffman; Julie A E Nelson; Kathryn M Kitrinos; Charles B Hicks; Joseph J Eron; Ronald Swanstrom
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Identification of primary HIV-1C infection in Botswana.

Authors:  V Novitsky; E Woldegabriel; C Wester; E McDonald; R Rossenkhan; M Ketunuti; J Makhema; G R Seage; M Essex
Journal:  AIDS Care       Date:  2008-08

9.  Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.

Authors:  Linda G Apuzzo; Florin Vaida; Joel E Gallant; Karin B Ernstrom; Susan J Little; Jean-Pierre Routy; Ann C Collier; Brian Conway; Martin H Markowitz; Frederick M Hecht; Bruce D Walker; Elizabeth Connick; Joseph B Margolick
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

10.  Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection.

Authors:  Matthew M Cousins; Oliver Laeyendecker; Geetha Beauchamp; Ronald Brookmeyer; William I Towler; Sarah E Hudelson; Leila Khaki; Beryl Koblin; Margaret Chesney; Richard D Moore; Gabor D Kelen; Thomas Coates; Connie Celum; Susan P Buchbinder; George R Seage; Thomas C Quinn; Deborah Donnell; Susan H Eshleman
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.